Abbvie Inc
NYSE:ABBV
Abbvie Inc
Total Current Liabilities
Abbvie Inc
Total Current Liabilities Peer Comparison
Competitive Total Current Liabilities Analysis
Latest Figures & CAGR of Competitors
Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Abbvie Inc
NYSE:ABBV
|
Total Current Liabilities
$37.8B
|
CAGR 3-Years
10%
|
CAGR 5-Years
17%
|
CAGR 10-Years
19%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Liabilities
$11.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
6%
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Liabilities
$18.4B
|
CAGR 3-Years
16%
|
CAGR 5-Years
6%
|
CAGR 10-Years
9%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Liabilities
$3.5B
|
CAGR 3-Years
24%
|
CAGR 5-Years
26%
|
CAGR 10-Years
24%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Liabilities
$3.4B
|
CAGR 3-Years
8%
|
CAGR 5-Years
19%
|
CAGR 10-Years
28%
|
|
Seagen Inc
NASDAQ:SGEN
|
Total Current Liabilities
$954.7m
|
CAGR 3-Years
17%
|
CAGR 5-Years
38%
|
CAGR 10-Years
25%
|
See Also
What is Abbvie Inc's Total Current Liabilities?
Total Current Liabilities
37.8B
USD
Based on the financial report for Dec 31, 2023, Abbvie Inc's Total Current Liabilities amounts to 37.8B USD.
What is Abbvie Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
19%
Over the last year, the Total Current Liabilities growth was 28%. The average annual Total Current Liabilities growth rates for Abbvie Inc have been 10% over the past three years , 17% over the past five years , and 19% over the past ten years .